Reflections on market access for personalized medicine: Recommendations for Europe

Value in Health

Volumn 16, Issue 6 SUPPL., 2013, Pages

  Payne, Katherine ^a   Annemans, Lieven ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

economic evaluation; personalized medicine; reimbursement

Indexed keywords

AZATHIOPRINE; NEUROLEPTIC AGENT; TAMOXIFEN;

ARTICLE; BREAST CANCER; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; EMPIRICISM; EUROPE; EUROPEAN UNION; GENOTYPE; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; NEUTROPENIA; OUTCOMES RESEARCH; PERSONALIZED MEDICINE; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; SCHIZOPHRENIA; SEMI STRUCTURED INTERVIEW;

ECONOMIC EVALUATION; PERSONALIZED MEDICINE; REIMBURSEMENT;

DECISION MAKING; EUROPEAN UNION; FINANCING, PERSONAL; HEALTH POLICY; HUMANS; INDIVIDUALIZED MEDICINE; INSURANCE, HEALTH, REIMBURSEMENT;

EID: 84884170973     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.06.010     Document Type: Article

References (27)

1. W.G.N. Newman Pharmacogenetics: Making Cancer Treatment Safer and More Effective 2010 Springer London
2. E.A. Fargher, K. Tricker, and B. Newman Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase (TPMT) testing prior to azathioprine prescription J Clin Pharm Ther 32 2007 187 195
3. ISPOR Global healthcare systems roadmap. Available from: http://www.ispor.org/HTARoadMaps/Default.asp. [Accessed May 7, 2013].
4. What is HTA? Available from: http://www.eunethta.eu/about-us/faq#t287n73. [Accessed May 7, 2013].
5. R. Busse, J. Orvain, and M. Velasco Best practice in undertaking and reporting health technology assessments: Working Group Report 4 Int J Technol Assess Health Care 18 2002 361 422
6. J.C. O'Donnell, S.V. Pham, and C.L. Pashos Health technology assessment in evidence-based health care reimbursement decisions around the world: an overview Value Health 12 Suppl. 2 2009 S1 S5
7. ISPOR Global healthcare systems roadmap: Greece. Available from: http://www.ispor.org/HTARoadMaps/Greece.asp. [Accessed May 7, 2013].
8. L.P. Garrison, and F. Austin Linking PGx-based diagnostics and drugs Health Aff 25 2006 1281 1290
9. K. Payne Fish and chips all round? Regulation of genetic-based technologies [editorial] Health Econ 18 2009 1233 1236
10. E. Faulkner, L. Annemans, and L. Garrison Challenges in the development and reimbursement of personalized medicine - payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR Personalized Medicine Special Interest Group Value Health 15 2012 1162 1171
11. L.M. Meckley, and P.J. Neumann Personalized medicine: factors influencing reimbursement Health Policy 94 2010 91 100
12. H.J. Fugel, M. Nuijten, and M. Postma Stratified medicine and reimbursement issues Front Pharmacol 3 2012 181
13. A.L. Beitelshees, and D.L. Veenstra Evolving research and stakeholder perspectives on pharmacogenomics JAMA 306 2011 1252 1253
14. National Institute for Health and Care Excellence. Methods guide for technology appraisal 2008. Available from: http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf. [Accessed May 7, 2013].
15. E.A. Fargher, C. Eddy, and W. Newman Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS Pharmacogenomics 8 2007 1511 1519
16. N. Crabb, M. Marlow, H. Bell, and A. Newland The NICE Diagnostics Assessment Programme Health Policy Technol 1 2012 5 7
17. Annemans L, Antoñanzas F, Boersma C, et al. Building a tool to evaluate and improve health investments in screening and diagnosis of disease. Project HISCREENDIAG. Available from: http://www.publichealth.ugent.be/index. cfm?objectid=8A6453A7-1143-DEB7-74C4FB9949BCFD0D. [Accessed May 7, 2013].
18. N. Fleeman, C. McLeod, and A. Bagust The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic valuation Health Technol Assess 14 2010 1 157
19. N. Fleeman, C. Martin Saborido, and K. Payne The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review Health Technol Assess 15 2011 1 102
20. W. Newman, K. Payne, and K. Tricker A pragmatic randomised controlled trial of thiopurine methyltransferase (TPMT) genotyping in the management of patients, prior to azathioprine treatment: the TARGET study Pharmacogenomics 12 2011 815 826
21. Thompson AR, Newman WG, Elliott RA, et al. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT testing for azathioprine. Value Health. In press.
22. A. Callard, K. Payne, and W.G. Newman Delivering a pharmacogenetic service in the NHS: is there a role for genetic counsellors? J Genet Couns 21 2012 527 535
23. W.G. Newman, B.F. Murphy, A. Callard, and K. Payne A role for genetic counsellors and clinical geneticists in pharmacogenetics? Clin Genet 82 2012 201 202
24. K. Payne, E.A. Fargher, and S. Roberts Valuing pharmacogenetic testing services: a comparison of patients' and healthcare professionals' preferences Value Health 14 2011 121 134
25. The European Personalised Medicine Association. Available from: http://www.epemed.org/. [Accessed May 7, 2013].
26. Garfield S. Advancing access to personalized medicine: a comparative assessment of European reimbursement systems. Available from: http://www.personalizedmedicinecoalition.org/sites/default/files/files/ PMC-Europe-Reimbursement-Paper-Final.pdf. [Accessed May 7, 2013].
27. The Personalized Medicine Coalition. Available from: www. personalizedmedicinecoalition.org. [Accessed May 7, 2013].